Completely agree about spatial transcriptomics being the future, and hope it gains the traction it deserves. This could also be e applied to sjogrens and other tissue-specific autoimmune manifestations to inform the most appropriate treatments that might avoid global immunosuppression.
20 minutes to see an RA patient? Not in pvt practice with 22 patients a day to pay your bills. What is the NNT for stating? Compare that to our NNT for MTX, aTNF, or any other drug we use in RA. What about getting RA patients off of low dose Prednisone and pushing them back to primary care to more aggressively manage their BP whose drugs have a much better NNT?
Completely agree about spatial transcriptomics being the future, and hope it gains the traction it deserves. This could also be e applied to sjogrens and other tissue-specific autoimmune manifestations to inform the most appropriate treatments that might avoid global immunosuppression.
20 minutes to see an RA patient? Not in pvt practice with 22 patients a day to pay your bills. What is the NNT for stating? Compare that to our NNT for MTX, aTNF, or any other drug we use in RA. What about getting RA patients off of low dose Prednisone and pushing them back to primary care to more aggressively manage their BP whose drugs have a much better NNT?